Business Information
The group's principal activities are to develop gene therapy and cell therapy products and technologies for the treatment of acquired and inherited diseases. The gene therapy products are designed to treat diseases by regulating cellular function at a genetic level. The cell therapy involves transplanting living cells into a patient to treat diseases, either in place of, or in combination with, other pharmaceuticals. Currently, the group has ongoing preclinical product development activities in the areas of cystic fibrosis, hemophilia a, arthritis, cancer, lysosomal storage disorders, cardiovascular diseases and aids prophylaxis. The product candidates under clinical development program include tgaavc-f for treatment of cystic fibrosis and tgddc-e1a for treatment of cancer.
|
|
Name |
Title
|
Email
|
| Jeremy Cook | Chmn. | N/A | | David Poston | VP - Finance, CFO, Treasurer | N/A | | Barrie Carter | Chief Scientific Officer, Exec. VP | N/A | | Pervin Anklesaria | VP - Therapeutic Development | N/A | | Richard Peluso | VP - Process Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 9,864 | (33,990) | | 2005 | 6,874 | (19,198) | | 2004 | 9,652 | (14,257)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
